277 related articles for article (PubMed ID: 25321194)
1. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
Komatsu S; Ichikawa D; Hirajima S; Nagata H; Nishimura Y; Kawaguchi T; Miyamae M; Okajima W; Ohashi T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Imoto I; Inazawa J; Otsuji E
Br J Cancer; 2015 Jan; 112(2):357-64. PubMed ID: 25321194
[TBL] [Abstract][Full Text] [Related]
2. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
Komatsu S; Imoto I; Tsuda H; Kozaki KI; Muramatsu T; Shimada Y; Aiko S; Yoshizumi Y; Ichikawa D; Otsuji E; Inazawa J
Carcinogenesis; 2009 Jul; 30(7):1139-46. PubMed ID: 19423649
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of ZRF1 is related to tumor malignant potential and a poor outcome of gastric carcinoma.
Imamura T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Ohashi T; Kiuchi J; Nishibeppu K; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Carcinogenesis; 2018 Feb; 39(2):263-271. PubMed ID: 29228320
[TBL] [Abstract][Full Text] [Related]
7. Effect of miRNA-200b on the proliferation of liver cancer cells via targeting SMYD2/p53 signaling pathway.
Fang W; Song L; Li Z; Meng P; Zuo S; Liu S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 47(10):1303-1314. PubMed ID: 36411681
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of YWHAZ relates to tumor cell proliferation and malignant outcome of gastric carcinoma.
Nishimura Y; Komatsu S; Ichikawa D; Nagata H; Hirajima S; Takeshita H; Kawaguchi T; Arita T; Konishi H; Kashimoto K; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Br J Cancer; 2013 Apr; 108(6):1324-31. PubMed ID: 23422756
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma.
Kashimoto K; Komatsu S; Ichikawa D; Arita T; Konishi H; Nagata H; Takeshita H; Nishimura Y; Hirajima S; Kawaguchi T; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Cancer Sci; 2012 Nov; 103(11):2021-6. PubMed ID: 22862969
[TBL] [Abstract][Full Text] [Related]
10. SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Wu L; Kou F; Ji Z; Li B; Zhang B; Guo Y; Yang L
Cell Death Dis; 2021 May; 12(5):439. PubMed ID: 33935284
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of denticleless E3 ubiquitin protein ligase homolog (DTL) is related to poor outcome in gastric carcinoma.
Kobayashi H; Komatsu S; Ichikawa D; Kawaguchi T; Hirajima S; Miyamae M; Okajima W; Ohashi T; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Oncotarget; 2015 Nov; 6(34):36615-24. PubMed ID: 26472028
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of YEATS4 contributes to malignant outcomes in gastric carcinoma.
Kiuchi J; Komatsu S; Imamura T; Nishibeppu K; Shoda K; Arita T; Kosuga T; Konishi H; Shiozaki A; Kubota T; Okamoto K; Fujiwara H; Ichikawa D; Tsuda H; Otsuji E
Am J Cancer Res; 2018; 8(12):2436-2452. PubMed ID: 30662802
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SET and MYND domain-containing protein 2 (
Zhang P; Ruan J; Weng W; Tang Y
Leuk Lymphoma; 2020 Feb; 61(2):437-444. PubMed ID: 31612757
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis.
Kim K; Ryu TY; Jung E; Han TS; Lee J; Kim SK; Roh YN; Lee MS; Jung CR; Lim JH; Hamamoto R; Lee HW; Hur K; Son MY; Kim DS; Cho HS
Exp Mol Med; 2023 May; 55(5):952-964. PubMed ID: 37121971
[TBL] [Abstract][Full Text] [Related]
15. SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Lai Y; Yang Y
Mol Cell Biochem; 2022 Sep; 477(9):2149-2159. PubMed ID: 32342276
[TBL] [Abstract][Full Text] [Related]
16. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.
Abu-Farha M; Lambert JP; Al-Madhoun AS; Elisma F; Skerjanc IS; Figeys D
Mol Cell Proteomics; 2008 Mar; 7(3):560-72. PubMed ID: 18065756
[TBL] [Abstract][Full Text] [Related]
17. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction.
Aratani K; Komatsu S; Ichikawa D; Ohashi T; Miyamae M; Okajima W; Imamura T; Kiuchi J; Nishibeppu K; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Oncotarget; 2017 Oct; 8(48):84112-84122. PubMed ID: 29137409
[TBL] [Abstract][Full Text] [Related]
19. SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency.
Boehm D; Jeng M; Camus G; Gramatica A; Schwarzer R; Johnson JR; Hull PA; Montano M; Sakane N; Pagans S; Godin R; Deeks SG; Krogan NJ; Greene WC; Ott M
Cell Host Microbe; 2017 May; 21(5):569-579.e6. PubMed ID: 28494238
[TBL] [Abstract][Full Text] [Related]
20. SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.
Wang Y; Jin G; Guo Y; Cao Y; Niu S; Fan X; Zhang J
Exp Cell Res; 2021 Jul; 404(2):112649. PubMed ID: 34015314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
